{"title":"An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder.","authors":"Justin Faden, Camila Ramirez, Vanessa Martinez, Leslie Citrome","doi":"10.1080/14737175.2024.2370349","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development. These include intramuscular, subcutaneous, long-acting oral, and implantable formulations.</p><p><strong>Areas covered: </strong>This review summarizes currently available and emerging long-acting risperidone formulations, including efficacy and safety data, and practical considerations aimed to help prescribers distinguish one formulation from another.</p><p><strong>Expert opinion: </strong>There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"761-771"},"PeriodicalIF":3.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2024.2370349","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development. These include intramuscular, subcutaneous, long-acting oral, and implantable formulations.
Areas covered: This review summarizes currently available and emerging long-acting risperidone formulations, including efficacy and safety data, and practical considerations aimed to help prescribers distinguish one formulation from another.
Expert opinion: There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs.
简介:长效注射(LAI)抗精神病药物有助于提高精神分裂症和双相情感障碍患者的治疗依从性。尽管如此,这些药物仍未得到充分利用。2003 年,肌肉注射利培酮成为第一种上市的 LAI 非典型抗精神病药物,从那时起,许多与之竞争的长效利培酮制剂已投放市场,还有更多选择正在积极开发中。这些制剂包括肌肉注射、皮下注射、长效口服和植入制剂:本综述总结了现有的和新出现的长效利培酮制剂,包括疗效和安全性数据,以及旨在帮助处方者区分不同制剂的实际注意事项:目前可供选择的LAI抗精神病药物越来越多,为患者和医疗服务提供者提供了个性化治疗的机会。精神分裂症和双相情感障碍患者坚持治疗的比例较低,而个性化护理有助于改善这一状况。利培酮 LAI 治疗方案包括五种已获美国食品药品管理局批准的方案,其他方案正在临床开发中。这些方案在给药方式、批准适应症、可用剂量强度、注射间隔、针头大小、注射量、储存和其他变量方面各不相同。处方医生应熟悉这些不同的选择,以帮助患者找到最适合其个人需求的药物。
期刊介绍:
Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points